Navigation Links
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Date:4/25/2008

is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

ISIS SAFE HARBOR STATEMENT

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of mipomersen in treating patients with high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerni
'/>"/>

SOURCE Genzyme Corp. and Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... York (PRWEB) August 23, 2014 Dermatophytic ... is one of the most common fungal infections of ... appearance of the nails such as, increased opaqueness and ... specifically describes the dermatophytic invasion of the nail plates ... artificial nail is applied as the nails are abraded ...
(Date:8/23/2014)... Texas (PRWEB) August 23, 2014 ... of the function of the myocardium (the heart ... failure; common symptoms are dyspnea (breathlessness) and peripheral ... are often at risk of dangerous forms of ... most common form of cardiomyopathy is dilated cardiomyopathy. ...
(Date:8/23/2014)... Pittsburgh, PA (PRWEB) August 23, 2014 ... mess when they gave a urine sample," said an ... the entire process easier and mess-free, I came up ... Device to allow urine samples to be collected from ... added peace of mind to patients and staff. The ...
(Date:8/23/2014)... 2014 "Many men refuse to touch ... up getting covered in urine and spit," said an ... bathroom situations, I came up with this hygienic device." ... a man raises the toilet seat before urinating. The ... This reduces contact with dirt and germs. The accessory ...
(Date:8/23/2014)... The report “Polycarbonate Resin Market by Applications & ... and segments the global polycarbonate resin market with ... consumption. It also identifies driving and restraining factors ... of trends, opportunities, burning issues, winning imperatives. The ... forecasted on the basis of major regions such ...
Breaking Medicine News(10 mins):Health News:Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4
... better prognosis, study finds , , FRIDAY, Dec. 12 (HealthDay News) ... the risk of getting breast cancer, but women who take ... risk of dying from the disease, a new study suggests. ... particular type of cancer that is easier to treat," explained ...
... Ariz., Dec. 12 Roberta Kalafut, D.O., just announced her ... to a close the worst abuses of power by the ... unjust disciplinary actions, particularly against her competitors, and stonewalling by ... , "We applaud Kalafut,s resignation," said AAPS Executive ...
... Fair Offers New Chemists and Chemical Engineers an Opportunity to ... , PRINCETON, N.J., Dec. 12 Informex ... the upcoming InformexUSA exhibition in San Francisco free of charge. ... 25 and under to learn more about the chemical technologies ...
... saw disease stabilize or improve, study shows , , ... combination of medicines designed to boost immune function ... interim results from an ongoing Mayo Clinic study. ... immunomodulatory drug called pomalidomide with dexamethasone (pom/dex) improved ...
... At its 12th annual holiday gala The,Teddy Bear ... Award to Steve,Mosko, President of Sony Pictures Television ... to children with special needs. Grammy(R),winning singer-songwriter Kenny ... of the Heart. Long standing friend and colleague ...
... YORK, Dec. 12 In his last public remarks as,the ... Lilly and Company (NYSE: LLY ), today said ... markets and regulatory environments,encourage and reward companies for the long-term, ... bench to the bedside. , ...
Cached Medicine News:Health News:HRT Users Who Get Breast Cancer Less Likely to Die 2Health News:HRT Users Who Get Breast Cancer Less Likely to Die 3Health News:AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next 2Health News:Informex Invites Young Chemists to Attend InformexUSA 2Health News:Informex Invites Young Chemists to Attend InformexUSA 3Health News:Combo Therapy Helps Multiple Myeloma Patients 2Health News:The Help Group's Teddy Bear Ball Salutes Sony Pictures Television President, Steve Mosko and Features Performance by Kenny Loggins 2Health News:Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies 2Health News:Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies 3
(Date:8/22/2014)... Aug. 22, 2014  Medical Science Liaisons serve as ... in the healthcare sector. As the impact of technology ... changing how Medical Science Liaisons (MSLs) interact with physicians ... using the tablet to not only share important disease ... coordinate thought leader interactions across geographies and therapeutic areas. ...
(Date:8/22/2014)... 22, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... instrument for any modern science laboratory as ... materials. It can be broadly classified into ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 /PRNewswire/ ... ) has announced the addition of the  ... to their offering.       (Logo: ... room with a sterile environment in a ... It is equipped with technically advanced equipment, ...
Breaking Medicine Technology:iPads Enhancing Medical Science Liaison Interactions with Thought Leaders, New Study Shows 2Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2
... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... Letter (CRL) from the U.S. Food and Drug Administration ... for AZ-004 (Staccato® loxapine), submitted as Adusuve™ Staccato® (loxapine) ... is issued by FDA,s Center for Drug Evaluation and ...
... Ltd. (NYSE Amex: CPD ) announced today that ... Executive Officer following the resignation of Jitendra N. Doshi as ... 1, 2010, due to personal and health-related reasons. ... many contributions during his years of service to the Company, ...
Cached Medicine Technology:Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA 2Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA 3Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA 4Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA 5Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 2Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 3Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 4
Right angled 5 mm blunt hook. Overall length: 9.9 inches....
Fine short working end. Overall length: 4.9 inches. Most popular size or model....
11.5 mm curved hook. Flat serrated handle with polished finish. Overall length: 5.9 inches....
Designed for manipulating one piece lenses. The "Y: hook is excellent for capturing haptics and centering the lens. Straight shaft with "Y" shaped tip. Round knurled handle with dull finish. Overall ...
Medicine Products: